$PXMD
PaxMedica Inc

2023 Q1 Form 10-K Financial Statement

#000155837023004966 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.814M $4.739M $8.817M
YoY Change 308.45% 258.5% 77.29%
% of Gross Profit
Research & Development $222.5K $238.1K $1.787M
YoY Change -79.22% -49.25% -19.65%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.037M $4.978M $10.60M
YoY Change 101.38% 177.9% 47.33%
Operating Profit -$4.037M -$10.60M
YoY Change 101.38% 47.33%
Interest Expense $3.928K -$3.930K $5.237K
YoY Change -100.19%
% of Operating Profit
Other Income/Expense, Net $202.9K -$81.56K -$4.197M
YoY Change -94.75% -101.02% 1371.67%
Pretax Income -$3.834M -$5.221M -$14.80M
YoY Change -305.73% -183.75% 44.7%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.834M -$5.221M -$14.80M
YoY Change -305.73% -183.75% 44.69%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30 -$1.69
Diluted Earnings Per Share -$0.30 -$0.41 -$1.69
COMMON SHARES
Basic Shares Outstanding 13.56M 11.78M 8.742M
Diluted Shares Outstanding 12.64M 8.742M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.986M $1.902M $1.902M
YoY Change 7972.6% 328.27% 328.27%
Cash & Equivalents $3.986M $1.902M
Short-Term Investments
Other Short-Term Assets $766.2K $302.4K $302.4K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.752M $2.204M $2.204M
YoY Change 9524.18% 396.37% 396.37%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $4.752M $2.204M $2.204M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $4.752M $2.204M $2.204M
YoY Change 778.58% 239.72% 239.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $480.2K $722.0K $722.0K
YoY Change -77.74% -1.94% -1.94%
Accrued Expenses $164.0K $1.019M $1.019M
YoY Change -81.3% 49.86% 49.86%
Deferred Revenue
YoY Change
Short-Term Debt $1.121M $173.5K $173.5K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.799M $2.096M $2.096M
YoY Change -79.09% -80.52% -80.52%
LONG-TERM LIABILITIES
Long-Term Debt $420.3K $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $420.3K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.799M $2.096M $2.096M
Total Long-Term Liabilities $420.3K $0.00 $0.00
Total Liabilities $2.220M $2.096M $2.096M
YoY Change -74.21% -80.52% -80.52%
SHAREHOLDERS EQUITY
Retained Earnings -$37.60M -$33.70M
YoY Change 77.95%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.533M $108.8K $108.8K
YoY Change
Total Liabilities & Shareholders Equity $4.752M $2.204M $2.204M
YoY Change 778.58% 239.72% 239.72%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$3.834M -$5.221M -$14.80M
YoY Change -305.73% -183.75% 44.69%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.000M -$3.067M -$6.100M
YoY Change 660.07% 145.68% 10.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.068M -594.4K 7.529M
YoY Change 460.16% 55.78%
NET CHANGE
Cash From Operating Activities -3.000M -3.067M -6.100M
Cash From Investing Activities
Cash From Financing Activities 5.068M -594.4K 7.529M
Net Change In Cash 2.068M -3.661M 1.429M
YoY Change -623.87% 170.31% -310.29%
FREE CASH FLOW
Cash From Operating Activities -$3.000M -$3.067M -$6.100M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8741678
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6666005
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001811623
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity Registrant Name
EntityRegistrantName
PaxMedica, Inc.
CY2022Q4 pxmd Shares Settled Liability Current
SharesSettledLiabilityCurrent
160949
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2095518
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10757729
CY2022Q4 us-gaap Liabilities
Liabilities
2095518
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6913492
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12035592
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6913492
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12035592
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41475
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0870387
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
303 South Broadway
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 125
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Tarrytown
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10591
CY2022 dei City Area Code
CityAreaCode
914
CY2022 dei Local Phone Number
LocalPhoneNumber
987-2876
CY2022 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
CY2022 dei Trading Symbol
TradingSymbol
PXMD
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13555392
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
New York, NY
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1901887
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
444087
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
302431
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2204318
CY2021Q4 us-gaap Assets Current
AssetsCurrent
444087
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
204779
CY2022Q4 us-gaap Assets
Assets
2204318
CY2021Q4 us-gaap Assets
Assets
648866
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
721955
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
736251
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
20000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
750
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1019071
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
680026
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
173543
CY2021Q4 pxmd Simple Agreement For Equity Liability Current
SimpleAgreementForEquityLiabilityCurrent
4824217
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4516485
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10108863
CY2021Q4 us-gaap Liabilities
Liabilities
10757729
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12035592
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1204
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
691
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33847607
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8828425
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33740016
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18938249
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108800
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10108863
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2204318
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
648866
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8816940
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4973245
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1787488
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2224555
CY2022 us-gaap Operating Expenses
OperatingExpenses
10604428
CY2021 us-gaap Operating Expenses
OperatingExpenses
7197800
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-10604428
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7197800
CY2022 us-gaap Interest Expense
InterestExpense
5237
CY2021 us-gaap Interest Expense
InterestExpense
2805856
CY2021 pxmd Gain Loss On Conversion Of Notes
GainLossOnConversionOfNotes
59890
CY2022 pxmd Gain Loss On Conversion Of Safe
GainLossOnConversionOfSafe
-5338808
CY2022 pxmd Gain Loss On Issuance Of Debt
GainLossOnIssuanceOfDebt
-391246
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-161563
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64500
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2430
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4197339
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3031171
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14801767
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10228971
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8741678
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6666005
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4628539
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3412782
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1335865
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10228971
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2022 pxmd Preferred Stock Stock Issued During Period Value New Issues Net Of Fees
PreferredStockStockIssuedDuringPeriodValueNewIssuesNetOfFees
300000
CY2022 pxmd Stock Issued During Period Value Conversion Of Simple Agreement For Future Equity Liability
StockIssuedDuringPeriodValueConversionOfSimpleAgreementForFutureEquityLiability
10000000
CY2022 pxmd Stock And Warrants Issued During Period Value Common Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
6023013
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1159500
CY2022 pxmd Stock Issued During Period Value Conversion Of Convertible Securities To Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesToPreferredStock
327993
CY2022 pxmd Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2009207
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
912580
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
230997
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4418134
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14801767
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108800
CY2022 us-gaap Profit Loss
ProfitLoss
-14801767
CY2021 us-gaap Profit Loss
ProfitLoss
-10228971
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4418134
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1335865
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2550780
CY2022 pxmd Fair Value Adjustment Of Convertible Notes
FairValueAdjustmentOfConvertibleNotes
272202
CY2022 pxmd Fair Value Adjustment Of Simple Agreement For Equity Liability
FairValueAdjustmentOfSimpleAgreementForEquityLiability
-163025
CY2021 pxmd Fair Value Adjustment Of Simple Agreement For Equity Liability
FairValueAdjustmentOfSimpleAgreementForEquityLiability
-175783
CY2022 pxmd Gain Loss On Conversion Of Safe
GainLossOnConversionOfSafe
-5338808
CY2022 pxmd Adjustments For Gain Loss On Issuance Of Debt
AdjustmentsForGainLossOnIssuanceOfDebt
-391246
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-161563
CY2021 pxmd Adjustments For Gain Loss On Conversion Of Notes
AdjustmentsForGainLossOnConversionOfNotes
59890
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1873192
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
458558
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
34500
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
255076
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
302431
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
94914
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
352277
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
19250
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-102053
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
238615
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
101502
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6071183
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5512639
CY2022 pxmd Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
6023013
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1240970
CY2022 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
300000
CY2021 pxmd Proceeds From Safe Investment
ProceedsFromSafeInvestment
5000000
CY2022 pxmd Payments Of Costs Incurred In Connection With Equity Purchase Agreement
PaymentsOfCostsIncurredInConnectionWithEquityPurchaseAgreement
35000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
166899
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7528983
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4833101
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1457800
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-679538
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444087
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1123625
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1901887
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
444087
CY2022 pxmd Stock Issued During Period Value Conversion Of Convertible Securities To Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesToPreferredStock
327993
CY2022 pxmd Conversion Of Notes Payable Value Shares Issued
ConversionOfNotesPayableValueSharesIssued
1159500
CY2021 pxmd Conversion Of Notes Payable Value Shares Issued
ConversionOfNotesPayableValueSharesIssued
3412782
CY2022 pxmd Conversion Of Simple Agreement For Future Equity Liability To Preferred Stock
ConversionOfSimpleAgreementForFutureEquityLiabilityToPreferredStock
10000000
CY2022 pxmd Warrants Exchanged For Common And Preferred Stock
WarrantsExchangedForCommonAndPreferredStock
2009207
CY2022 pxmd Reclassification Of Warrants To Equity During Period
ReclassificationOfWarrantsToEquityDuringPeriod
912580
CY2022 pxmd Non Cash Transaction Shares Settled Liability
NonCashTransactionSharesSettledLiability
160949
CY2022 pxmd Non Cash Transaction Equity Purchase Agreement Unpaid Costs
NonCashTransactionEquityPurchaseAgreementUnpaidCosts
195997
CY2021 pxmd Unpaid Offering Costs
UnpaidOfferingCosts
37880
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. Organization and Description of Business Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PaxMedica, Inc. (Formerly Purinix Pharmaceuticals LLC) (the “Company”) is a clinical stage biopharmaceutical company organized as a Delaware limited liability company on April 5, 2018 (“Inception”) to focus on the development of drug candidates for the treatment of autism spectrum disorder (ASD), Fragile X syndrome tremor-ataxia (FXTAS) and Human African Trypanosomiasis (HAT).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;text-decoration-line:none;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 9, 2022, the Company entered into an underwriting agreement relating to the public offering of its common stock, par value $0.0001 per share. The Company agreed to sell 1,545,454 shares of its common stock to the underwriters, at a purchase price per share of $4.83 (the offering price to the public of $5.25 per share minus the underwriters’ discount), pursuant to the Company’s registration statement on Form S-1 (File No. 333-239676), as amended, under the Securities Act of 1933, that was filed by the Company under Rule 462(b) under the Securities Act. The Company also granted the underwriters a 45-day option to purchase up to 231,818 additional shares of common stock to cover over-allotments. On August 30, 2022, the Company received net proceeds from its public offering of approximately $6.0 million, net of underwriter fees and commissions of approximately $0.8 million, and offering costs of approximately $1.4 million. In connection with its public offering the Company issued 108,181 warrants to purchase shares of the Company’s common stock with an exercise price of $6.5625 per share.</p>
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q4 pxmd Working Capital
WorkingCapital
100000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33700000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14800000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6100000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of the 2022 Notes, valuation of the SAFE liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash.</p>
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3278340
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3006419
CY2021Q4 us-gaap Share Price
SharePrice
12.05
CY2021Q4 pxmd Simple Agreement For Equity Investment Post Money Valuation
SimpleAgreementForEquityInvestmentPostMoneyValuation
150000000
CY2021Q4 pxmd Common Stock Shares Outstanding Considered For Determination Of Post Money Valuation
CommonStockSharesOutstandingConsideredForDeterminationOfPostMoneyValuation
12444251
CY2021Q4 pxmd Common Stock Shares Outstanding Considered For Determination Of Post Money Valuation
CommonStockSharesOutstandingConsideredForDeterminationOfPostMoneyValuation
12444251
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6913492
CY2021Q4 pxmd Potential Shares From Initial Public Offering
PotentialSharesFromInitialPublicOffering
2703776
CY2021Q4 pxmd Restricted Stock Units Considered For Determination Of Post Money Valuation
RestrictedStockUnitsConsideredForDeterminationOfPostMoneyValuation
1377999
CY2021Q4 pxmd Common Stock Warrants For Safe Investment
CommonStockWarrantsForSafeInvestment
1034176
CY2021Q4 pxmd Simple Agreement For Future Equity Shares
SimpleAgreementForFutureEquityShares
414808
CY2021Q4 pxmd Simple Agreement For Future Equity Shares
SimpleAgreementForFutureEquityShares
414808
CY2021Q4 pxmd Simple Agreement For Future Equity Investment
SimpleAgreementForFutureEquityInvestment
5000000.0
CY2021Q4 us-gaap Share Price
SharePrice
12.05
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
667000
CY2022Q3 pxmd Number Of Warrants Converted Into Common Stock Or Preferred Shares
NumberOfWarrantsConvertedIntoCommonStockOrPreferredShares
750000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
510297
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
680026
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
269753
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
162021
CY2022Q4 pxmd Research And Development
ResearchAndDevelopment
77000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1019071
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
680026
CY2021 pxmd Proceeds From Safe Investment
ProceedsFromSafeInvestment
5000000.0
CY2022Q3 pxmd Stock Issued During Period Value Conversion Of Simple Agreement For Future Equity Liability
StockIssuedDuringPeriodValueConversionOfSimpleAgreementForFutureEquityLiability
10000000.0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-200000
CY2022Q4 pxmd Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
447000
CY2022 pxmd Number Of Employees Terminated
NumberOfEmployeesTerminated
2
CY2022 pxmd Number Of Board Members Terminated
NumberOfBoardMembersTerminated
2
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
500000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1300000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022 pxmd Non Cash Transaction Shares Settled Liability
NonCashTransactionSharesSettledLiability
200000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12035592
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3400000
CY2022Q3 pxmd Simple Agreement For Equity Liability Current
SimpleAgreementForEquityLiabilityCurrent
5000000.0
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
14100000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4800000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2600000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3687000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2030000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
29000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
166000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4830000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2207000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4830000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2207000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.050
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.018
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.092
CY2022 pxmd Effective Income Tax Rate Reconciliation Deduction Debt Conversion Percent
EffectiveIncomeTaxRateReconciliationDeductionDebtConversionPercent
0.078
CY2021 pxmd Effective Income Tax Rate Reconciliation Deduction Debt Conversion Percent
EffectiveIncomeTaxRateReconciliationDeductionDebtConversionPercent
0.067
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.007
CY2022 pxmd Effective Income Tax Rate Reconciliation Deduction Warrant Liability Percent
EffectiveIncomeTaxRateReconciliationDeductionWarrantLiabilityPercent
-0.027
CY2021 pxmd Effective Income Tax Rate Reconciliation Deduction Warrant Liability Percent
EffectiveIncomeTaxRateReconciliationDeductionWarrantLiabilityPercent
0.009
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.177
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.083
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
20000

Files In Submission

Name View Source Status
pxmd-20221231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001558370-23-004966-index-headers.html Edgar Link pending
0001558370-23-004966-index.html Edgar Link pending
0001558370-23-004966.txt Edgar Link pending
0001558370-23-004966-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pxmd-20221231.xsd Edgar Link pending
pxmd-20221231x10k.htm Edgar Link pending
pxmd-20221231x10k001.jpg Edgar Link pending
pxmd-20221231x10k002.jpg Edgar Link pending
pxmd-20221231x10k003.jpg Edgar Link pending
pxmd-20221231x10k004.jpg Edgar Link pending
pxmd-20221231xex23d1.htm Edgar Link pending
pxmd-20221231xex31d1.htm Edgar Link pending
pxmd-20221231xex31d2.htm Edgar Link pending
pxmd-20221231xex32d1.htm Edgar Link pending
pxmd-20221231xex32d2.htm Edgar Link pending
pxmd-20221231xex4d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
pxmd-20221231_lab.xml Edgar Link unprocessable
pxmd-20221231_def.xml Edgar Link unprocessable
pxmd-20221231_pre.xml Edgar Link unprocessable
pxmd-20221231x10k_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending